Co-infection due to the hepatitis C virus and the human immunodeficiency virus in a population at risk

Authors

  • Odris Lescay Bell Hospital General Docente “Dr. Juan Bruno Zayas Alfonso”, Universidad de Ciencias Médicas, Santiago De Cuba
  • Elba Patricia Cabezas Niubo Hospital General Docente “Dr. Juan Bruno Zayas Alfonso”, Universidad de Ciencias Médicas, Santiago De Cuba
  • María Janine Suárez Suárez Hospital General Docente “Dr. Juan Bruno Zayas Alfonso”, Universidad de Ciencias Médicas, Santiago De Cuba
  • Jesús Fernández Duharte Hospital General Docente “Dr. Juan Bruno Zayas Alfonso”, Universidad de Ciencias Médicas, Santiago De Cuba
  • Daisy Martén Maren Hospital General Docente “Dr. Juan Bruno Zayas Alfonso”, Universidad de Ciencias Médicas, Santiago De Cuba

Keywords:

viral co-infection, hepatitis C virus, human immunodeficiency virus, liver functional tests, population at risk, secondary health care.

Abstract

A descriptive, prospective and cross-sectional study of 25 patients with diagnosis of co-infection due to hepatitis C virus and that of the human immunodeficiency who had been referred to "Dr. Juan Bruno Zayas Alfonso" Teaching General Hospital in Santiago de Cuba, was carried out from January, 2012 to the same month in 2014, in order to determine the epidemiological, clinical and humoral characteristics in them.  In the series it was obtained that the infection due to both viruses was more frequent in the 30-39 age group (36.0%), in male sex (96.0%) and in the members of the multiple risks group (64.0%). Most of the patients had been diagnosed with the co-infection in less than the 3 years, they stated more than one clinical feature and presented high results in the liver functional tests. 

Downloads

Download data is not yet available.

References

1. Branch AD, Van Natta ML, Vachon ML, Dieterich DT, Meinert CL, Jabs DA. Mortality in HCV-infected patients with a diagnosis of AIDS in the era of combination anti-retroviral therapy. Clin Infect Dis. 2012; 26(8): 971-97.

2. Organización Mundial de la Salud. Determinantes sociales de la salud. Ginebra: OMS; 2008 [citado 5 Mar 2015]. Disponible en: http://www.who.int/social_determinants/es/index.html

3. Cargill VA. HIV/hepatitis C virus co-infection: its human face. AIDS. 2005; 19(Suppl.): 1-2.

4. Tural C, Fuster D, Tor J, Ojanguren I, Sirera G, Ballesteros A, et al. Time on antiretroviral therapy is a protective factor for liver fibrosis in HIV and hepatitis C virus (HCV) co-infected patients. J Viral Hepat. 2003; 10(2): 118-25.

5. Pol S, Couzigou P, Bourlière M, Abergel A, Combis JM, Larrey D, et al. A randomized trial of ribavirin and interferon-alpha vs. interferon-alpha alone in patients with chronic hepatitis C who were non-responders to a previous treatment. J Hepatol. 1999; 31(1): 1-7.

6. Alexander I, Millen J, Fallows D. Sida global: verdades y mentiras: herramientas para luchar contra la pandemia del siglo XXI. Barcelona: Paidós; 2004.

7. Rivera Landa DE. Prevalencia de la co-infección VIH/SIDA-hepatitis viral B/C y los determinantes sociales en usuarios del CAPASITS del Hospital “Dr. Luis F. Nachón”, Xalapa, Ver [tesis]. Veracruz: Universidad Veracruzana; 2011 [citado 5 Mar 2015]. Disponible en: http://www.uv.mx/msp/files/2014/10/TESIS003-2011.pdf

8. Padrón Alfonso A, Reyes Corcho A, Hernández Monzón V, Jam Morales BC, Bouza Jiménez Y, Cabanes P, et al. Coinfección VIH-hepatitis B y C en la provincia de Cienfuegos. Rev Cubana Med Trop. 2008 [citado 5 Mar 2015]; 60(2). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0375-07602008000200007

9. Bello Corredor M, Montalvo Villalba MC, Rodríguez Lay LA, Valdés Alonso L, Sariego Frómeta S, Pedroso Flaquet P, et al. Hepatitis C en pacientes VIH positivos. Rev Cubana Med Trop. 2008 [citado 5 Mar 2015]; 60(3). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0375-07602008000300012

10. Arús Soler E. Historia natural de la infección por el virus de la hepatitis C. Rev Cubana Med. 2006 [citado 5 Mar 2015]; 45(1). Disponible en: http://www.bvs.sld.cu/revistas/med/asul_06/med28a_06.htm

11. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management and treatment of hepatitis C: an update. Hepatology. 2009; 49(4): 1335-74.

12. Gordon SC, Bayati N, Silverman AL. Clinical outcome of hepatitis C as a function of mode of transmission. Hepatology. 1998; 28(2): 562-7.

13. White EF, Garfein RS, Brouwer KC, Lozada R, Ramos R, Firestone-Cruz M, et al. Prevalence of hepatitis C virus and HVI infection among injection drug users in two Mexican cities bordering U.S. Salud Pública Mex. 2009; 49(3): 165-72.

14. Stubbe L, Soriano V, Antunes F. Hepatitis C in the EuroSida cohort of European HIV-infected patients: prevalence and prognostic value. In: The XII International AIDS Conference. Ginebra: [s.n.]; 1998.

15. Akin M, Fernández MI, Bowen GS, Warren JC. HIV risk behaviors of Latin American and Caribbean men who have sex with men in Miami, Florida, USA. Rev Panam Salud Pública. 2008; 23(5): 341-8.

16. García A, Noguer I, Cowgill K. Panorama epidemiológico y repercusiones económicas. In: Noguer I, Cowgill K. El VIH/SIDA en países de América Latina. Washington, D.C.: OPS; 2004. p. 54.

17. Sánchez F. VIH SIDA y Hepatitis C, una combinación mortal. 2011. 5 ed. Mc Graw – Hill Interamericana Editores. México.

18. Laufer NL, Quarleri JF, Bouzas MB, Pérez HM, Salomón H, Cahn PE. Coinfecciones por HVB y HVC en pacientes HIV positivos en la "era HAART": nuevos desafíos. Medicina (B. Aires). 2007; 67(1): 82-91.

19. Michaels AJ, Nelson DR. New therapies in the management of hepatitis C virus. Curr Opin Gastroenterol. 2010; 26(3): 196-201.

Downloads

Published

2016-10-13

How to Cite

1.
Lescay Bell O, Cabezas Niubo EP, Suárez Suárez MJ, Fernández Duharte J, Martén Maren D. Co-infection due to the hepatitis C virus and the human immunodeficiency virus in a population at risk. MEDISAN [Internet]. 2016 Oct. 13 [cited 2025 Jun. 2];20(10). Available from: https://medisan.sld.cu/index.php/san/article/view/178

Issue

Vol. 20 No. 10 (2016): MEDISAN

Section

Original Articles

License

All the articles can be downloaded or read for free. The journal does not charge any amount of money to the authors for the reception, edition or the publication of the articles, making the whole process completely free. Medisan has no embargo period and it is published under the license of Creative Commons, International Non Commercial Recognition 4.0, which authorizes the copy, reproduction and the total or partial distribution of the articles in any format or platform, with the conditions of citing the source of information and not to be used for profitable purposes.